Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
29 hedge funds and large institutions have $52M invested in Evelo Biosciences, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 2 reducing their positions, and 2 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 2
360% more capital invested
Capital invested by funds: $11.3M → $52M (+$40.7M)
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
16% more funds holding
Funds holding: 25 → 29 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$36.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.8M |
| 3 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$8.86M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$556K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$6.84K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$242 |
EVLO Hedge Fund Activity: Q3 2023 in Review
29 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q3 2023, worth a combined $52M — up 360% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EVLO positions and 2 closed out — a net gain of 4 holders — while 16 added to existing stakes and 2 trimmed.
The largest buyer was Flagship Pioneering, adding an estimated $36.9M. The largest seller was Barclays, cutting an estimated $556K.
- 29 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q3 2023, up from 25 in Q2 2023.
- Funds reported $52M of Evelo Biosciences, Inc. Common Stock stock for Q3 2023, up 360% quarter-over-quarter.
- 6 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of +4 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q3 2023 was Flagship Pioneering, an estimated $36.9M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q3 2023 was Barclays, an estimated $556K sold.
Based on aggregated 13F filings for Q3 2023.